Early Alzheimer's increased connectivity lowered by cancer drug in the lab

Neurons exposed to amyloid-beta formed more connections (SSBs = single synaptic boutons), which could be lessened with cancer drug eFT508.
Image Credit: Figure reproduced from Wu et al. 2026

Scientific Frontline: Extended "At a Glance" Summary: Early Alzheimer's Hyperconnectivity and eFT508

The Core Concept: In the earliest stages of Alzheimer's disease, typically correlating with Mild Cognitive Impairment (MCI), low levels of the amyloid-beta protein induce an abnormal increase in neural connections (hyperconnectivity) prior to widespread cell death and memory loss.

Key Distinction/Mechanism: Challenging the traditional model that Alzheimer's begins primarily with synapse loss, this research demonstrates that the disease may actually initiate with too many poorly organized connections. Amyloid-beta rewires, rather than simply increases or decreases, cellular protein production, pushing neurons into an unstable state. The experimental cancer drug eFT508, which targets MAP kinase interacting kinase (MNK), successfully prevented this hyperconnectivity and restored normalized protein production in laboratory models.

Major Frameworks/Components:

• Amyloid-Beta Induced Synaptogenesis: Exposure to low doses of amyloid-beta over a short five-day period triggers hyperconnectivity and creates a self-reinforcing loop by upregulating the amyloid precursor protein.
• Expansion Microscopy: A state-of-the-art imaging technique that expands biological samples 5 to 6 times, enabling researchers to visualize and quantify individual synapses as small as 30 nanometers.
• Liquid-Chromatography Mass-Spectrometry: An analytical method used to profile internal neuronal changes, identifying 49 specific proteins whose production was altered by amyloid-beta exposure.
• MNK Inhibition (eFT508): The pharmacological mechanism utilized by the repurposed cancer drug to decrease neuroinflammation, inhibit abnormal protein synthesis, and restore approximately 70% of altered protein production.

Relax study by Dresden scientists: Innovative combination therapy shows promising efficacy in aggressive leukemia

Alongside his colleague Dr. Leo Ruhnke (right side), Prof. Christoph Röllig (left side) designed and supervised the RELAX study
Photo Credit: Courtesy of Dresden University

Scientific Frontline: "At a Glance" Summary: Acute Myeloid Leukemia Combination Therapy

• Main Discovery: The addition of the BCL2 inhibitor venetoclax to intensive chemotherapy substantially improves treatment outcomes for patients suffering from relapsed or refractory acute myeloid leukemia.
• Methodology: Researchers conducted a multicenter phase 1/2 clinical trial known as the RELAX study to evaluate the tolerability and efficacy of combining a standard chemotherapy regimen of cytarabine and mitoxantrone with venetoclax.
• Key Data: The experimental combination therapy achieved a 75 percent complete remission rate, representing a stark increase over the 40 percent remission rate historically observed with conventional chemotherapy alone.
• Significance: By effectively suppressing rapidly growing leukemia cells, this therapeutic approach successfully qualifies a significantly larger proportion of treatment-resistant patients for potentially curative stem cell transplantations.
• Future Application: The treatment regimen is currently undergoing expanded evaluation in over 150 additional patients and demonstrates strong potential to become the new standard of care for treating acute myeloid leukemia relapses.
• Branch of Science: Hematology, Oncology, and Clinical Pharmacology.
• Additional Detail: The therapeutic combination maintained high efficacy even against particularly resistant genetic variants of the disease, with the foundational findings formally published in The Lancet Haematology.

Blood clot sting in the tail of scorpion venom

Arabian fat-tailed scorpion (Androctonus crassicauda)
Photo Credit: Per-Anders Olsson
(CC BY-SA 4.0)
Changes made: Enhanced and enlarged by Scientific Frontline

Scientific Frontline: Extended "At a Glance" Summary: Procoagulant Properties of Fat-Tailed Scorpion Venom

The Core Concept: A recent study has revealed that the highly lethal, primarily neurotoxic venom of fat-tailed scorpions (genus Androctonus) possesses an additional, previously unknown biochemical mechanism that induces rapid blood clotting in humans.

Key Distinction/Mechanism: While the venom is known to overwhelm the nervous system to cause heart failure, it simultaneously exhibits a profound procoagulant effect by biochemically hijacking the human blood coagulation cascade. Specifically, the venom activates major clotting Factors VII and X—a process dependent on activated Factor V. Unlike the neurotoxic symptoms, this clotting activity is not neutralized by standard antivenoms, but can be blocked by specific small-molecule metalloprotease inhibitors.

Major Frameworks/Components:

• Dual-Action Pathology: The venom operates on two independent lethal pathways: neurotoxicity (nervous system overload) and procoagulation (abnormal blood clotting).
• Clotting Factor Activation: The venom's enzymes act with high precision on human physiology, specifically targeting and accelerating Factors VII and X.
• Adjunct Enzyme Inhibition: Testing revealed that the metalloprotease inhibitors marimastat and prinomastat successfully neutralize the venom's clotting effects, identifying the specific enzyme class responsible and proving the necessity of targeted adjunct therapies alongside traditional antivenom.

‘The munchies’ are real and could benefit those with no appetite

Carrie Cuttler, right, an associate professor in the Department of Psychology at WSU, points to a screen displaying data about caloric intake and THC, while Ryan McLaughlin, an associate professor in the Department of Integrative Physiology and Neuroscience in WSU’s College of Veterinary Medicine, looks on. Cuttler and McLaughlin co-direct The Health and Cognition (THC) Lab
Photo Credit: Ted S. Warren, College of Veterinary Medicine

Scientific Frontline: "At a Glance" Summary

• Main Discovery: Cannabis consumption induces an acute cognitive appetite response, universally stimulating hunger independently of an individual's sex, age, weight, or prior food intake.
• Methodology: Researchers conducted a randomized clinical trial with 82 human volunteers who vaped either 20 milligrams of cannabis, 40 milligrams of cannabis, or a placebo, while parallel animal studies monitored food-seeking behavior in rats exposed to the drug.
• Key Data: Participants exposed to cannabis consumed significantly higher food volumes than the control group, displaying strong preferences for specific items like beef jerky and water even when previously satiated.
• Significance: The research confirms that appetite stimulation from tetrahydrocannabinol is strictly brain-mediated, occurring when the compound stimulates cannabinoid receptors in the hypothalamus to override natural satiety signals.
• Future Application: Findings provide a physiological foundation for developing targeted medicinal cannabis therapies to combat wasting syndromes and severe appetite loss in patients undergoing chemotherapy or managing chronic conditions like HIV and AIDS.
• Branch of Science: Neuroscience and Pharmacology
• Additional Detail: Pharmacology trials demonstrated that blocking cannabinoid receptors in the peripheral nervous system failed to curb appetite, whereas blocking identical receptors in the brain successfully suppressed the drug-induced hunger response.

Scientists unlock a massive new ‘color palette’ for biomedical research by synthesizing non-natural amino acids

Peptides have found use in over 80 drugs worldwide since insulin was first synthesized in the 1920s.
Image Credit: Scientific Frontline

Scientific Frontline: "At a Glance" Summary

• Main Discovery: Researchers at UC Santa Barbara developed an efficient technique to synthesize non-natural amino acids that are immediately ready for direct use in peptide construction without extra modification steps.
• Methodology: The team utilized gold catalysis to generate stereoselective amino acids from inexpensive chemical ingredients, subsequently assembling them into peptides through a rinse-and-repeat process on a resin scaffold.
• Key Data: While lifeforms naturally utilize only 22 amino acids to build proteins, this breakthrough expands the available biochemical toolkit from a limited 22-molecule palette to potentially hundreds of noncanonical variations.
• Significance: The ability to easily incorporate non-natural amino acids allows drug designers to armor-plate peptide therapeutics against destructive bodily enzymes and force them into specific shapes for superior receptor binding.
• Future Application: Researchers plan to automate the synthesis process to provide non-chemists in drug development and materials research with accessible, low-friction access to these expanded molecular building blocks.
• Branch of Science: Biochemistry, Pharmacology, and Materials Science.
• Additional Detail: Unlike existing approaches that require complex manipulation, this method produces amino acids where the acid group is already primed to react, leaving only the amino group requiring unmasking.

Psychopharmacology: In-Depth Description

Psychopharmacology is the scientific study of the effects drugs have on mood, sensation, thinking, and behavior. It is an interdisciplinary field that merges the principles of neuroscience, pharmacology, and psychology to understand how chemical agents interact with the nervous system to alter mental states. Its primary goals are to elucidate the biological mechanisms of mental disorders and to develop effective pharmaceutical treatments to manage or cure these conditions.

Cancer treatment: optimization of CAR T-cell therapy

LMU physician Sebastian Kobold
Photo Credit: © LMU / Stephan Höck

Scientific Frontline: Extended "At a Glance" Summary

The Core Concept: An advanced form of immunotherapy in which Chimeric Antigen Receptor (CAR) T cells are genetically engineered to resist immunosuppressive signals found within solid tumors, enabling the immune system to effectively destroy cancer cells that were previously resistant to treatment.

Key Distinction/Mechanism: While standard CAR T-cell therapy is highly effective against blood cancers, it often fails against solid tumors because a metabolite called prostaglandin E2 (PGE2) suppresses the T cells' function. This new approach involves removing the specific receptors on the T cells that PGE2 binds to; by eliminating these binding sites, the T cells become "deaf" to the tumor's suppression signal and remain active to attack the malignancy.

Origin/History:

• 2024: Professor Sebastian Kobold’s research group at LMU University Hospital identifies that PGE2 blocks T cells in the tumor vicinity.
• 2026: The team, in cooperation with the University of Tübingen, publishes their success in engineering PGE2-resistant cells in Nature Biomedical Engineering.

Major Frameworks/Components:

• Chimeric Antigen Receptor (CAR) T Cells: Patient-derived immune cells modified to recognize specific cancer proteins (like CD19).
• Prostaglandin E2 (PGE2): An immunosuppressive metabolite in the tumor microenvironment that normally inhibits immune response.
• Receptor Knockout: The genetic removal of PGE2 receptors from T cells to prevent immunosuppression.

Established cancer drug reactivates immunotherapy

Professor Florian Bassermann and his team are researching the role of the ubiquitin system in cancer. Insights from their basic research are quickly benefiting patients as well.
Photo Credit: Kathrin Czoppelt / TUM Klinikum

Scientific Frontline: Extended "At a Glance" Summary

The Core Concept: Researchers have identified that an existing cancer drug, carfilzomib, can restore the efficacy of CAR-T cell therapy in multiple myeloma patients by preventing cancer cells from hiding their surface markers.

Key Distinction/Mechanism: A common resistance mechanism in immunotherapy involves cancer cells degrading specific surface antigens (like BCMA) via the ubiquitin-proteasome system, effectively becoming invisible to engineered T cells. Unlike therapies that require new drug discovery, this method utilizes carfilzomib—a known proteasome inhibitor—to block this degradation process, restabilizing the antigens on the cell surface and allowing the CAR-T cells to recognize and attack the cancer again.

Origin/History: The findings were published in the journal Blood in 2026 by a team led by Prof. Florian Bassermann and Dr. Leonie Rieger at the Technical University of Munich (TUM).

Major Frameworks/Components:

• CAR-T Cell Therapy: A treatment where a patient's T cells are genetically modified to target cancer cells.
• BCMA (B Cell Maturation Antigen): The specific protein target on multiple myeloma cells.
• Ubiquitin-Proteasome System: The intracellular network responsible for degrading proteins, identified here as the cause of BCMA loss.
• Carfilzomib: An approved drug that inhibits the proteasome, preventing antigen degradation.

Tiny Worm Offers Clues to Combat Chemotherapy Neurotoxicity

Caenorhabditis elegans
Image Credit: Scientific Frontline

Scientific Frontline: "At a Glance" Summary

• Main Discovery: Sildenafil citrate and the experimental compound Resveramorph-3 significantly mitigate the neurological dysfunction caused by the chemotherapy drug docetaxel.
• Methodology: Researchers utilized the roundworm Caenorhabditis elegans to model neurotoxicity, exposing the organisms to acute and chronic docetaxel doses and quantifying recovery from shock-induced seizure-like behaviors using an electroconvulsive assay.
• Key Data: While docetaxel exposure consistently delayed recovery in the model, treatment with the identified compounds significantly reduced seizure severity and duration; this addresses a condition affecting up to 85% of cancer patients.
• Significance: The study validates a rapid, in vivo platform for screening neuroprotective drugs and identifies specific agents that may prevent the debilitating neuropathy that often forces patients to discontinue life-saving cancer therapy.
• Future Application: Development of co-therapies administered alongside taxane-based chemotherapy to protect nerve function and improve patient quality of life during treatment.
• Branch of Science: Neuroscience, Pharmacology, and Oncology.
• Additional Detail: Sildenafil citrate appears to stabilize neuronal activity through protein kinase G signaling and potassium channel regulation, while Resveramorph-3 provides structural neuroprotection.

UC Irvine scientists create powerful enzyme that quickly, accurately synthesizes RNA

“This work shows that enzymes are far more adaptable than we once thought,” says study leader John Chaput, UC Irvine professor of pharmaceutical sciences. “By harnessing evolution, we can create new molecular tools that open the door to advances in RNA biology, synthetic biology and biomedical innovation.”
Photo Credit: Steve Zylius / UC Irvine

Scientific Frontline: "At a Glance" Summary

• Main Discovery: Researchers engineered a novel DNA polymerase, designated C28, that efficiently synthesizes RNA with high fidelity and speed, a capability that natural DNA polymerases are biologically designed to reject.
• Methodology: The team utilized directed evolution within a high-throughput, single-cell screening platform to recombine related polymerase genes, evaluating millions of variants to identify unexpected structural solutions without manually redesigning the active site.
• Key Data: The C28 enzyme contains dozens of specific mutations selected from a pool of millions of variants, enabling it to operate at near-natural speeds while accommodating chemically modified RNA building blocks.
• Significance: This breakthrough overcomes fundamental biological barriers to RNA synthesis, creating a versatile tool that can also perform reverse transcription and generate hybrid DNA-RNA molecules using standard PCR techniques.
• Future Application: The enzyme provides critical functionality for developing next-generation mRNA vaccines and RNA-based therapeutics that require customized or chemically modified RNA sequences.
• Branch of Science: Biochemistry, Pharmaceutical Sciences, and Synthetic Biology.
• Additional Detail: Led by Professor John Chaput and published in Nature Chemical Biology, this research demonstrates that directed evolution can unlock molecular functions nonexistent in nature, such as the ability of a DNA polymerase to transcribe RNA.

UrFU Chemists Have Synthesized New Compound to Fight Cancer

If successful in trials, such drugs could reach the Russian market in 7-10 years.
Photo Credit: Vladimir Petrov

Scientific Frontline: Extended "At a Glance" Summary

The Core Concept: Researchers at Ural Federal University (UrFU) have synthesized a new family of chemical compounds that selectively target and suppress the growth of specific tumor cells by halting their division rather than immediately destroying them.

Key Distinction/Mechanism: Unlike traditional chemotherapy drugs that are often cytotoxic (cell-killing) and harmful to healthy tissues, these new compounds utilize a cytostatic mechanism. They effectively "freeze" the tumor by blocking Cyclin-dependent kinase 2 (CDK2), a protein critical for cell division, thereby preventing tumor proliferation with reduced toxicity to healthy cells.

Origin/History:

• Discovery Context: Developed by the UrFU Scientific, Educational and Innovative Center of Chemical and Pharmaceutical Technologies.
• Publication: Findings and descriptions of the compounds were published in the international journal ChemMedChem.
• Timeline: Announced in February 2026, with potential market availability estimated in 7-10 years pending successful trials.

Tiny mutation, big impact on schizophrenia treatment

Image Credit: Scientific Frontline

Scientific Frontline: "At a Glance" Summary

• Main Discovery: Researchers identified a rare genetic mutation, C182F, within the TAAR1 brain receptor that completely negates the efficacy of newer schizophrenia treatments by structurally locking the receptor in an inactive state.
• Methodology: The study employed advanced cell biology assays and 500-nanosecond molecular dynamics simulations to analyze the variant, which was originally isolated from an Indian family with a history of schizophrenia.
• Key Data: In the homozygous state, the mutation caused a complete loss of receptor signaling function and reduced protein surface expression by approximately 40%, while heterozygous cells retained only about 50% activity.
• Significance: This discovery explains the clinical failure of promising TAAR1 agonists like ulotaront in certain patients, revealing that the mutation eliminates the critical disulfide bond "tent pole" needed for the drug to bind effectively.
• Future Application: Standard psychiatric care may evolve to include mandatory genetic screening for TAAR1 variants prior to prescribing specific antipsychotics to ensure alignment with the patient's pharmacogenomic profile.
• Branch of Science: Pharmacogenomics and Molecular Psychiatry.
• Additional Detail: While rare globally, the C182F mutation occurs more frequently in South Asian populations, highlighting a specific demographic necessity for targeted genetic testing in drug development.

New cancer-killing material developed by Oregon State University nanomedicine researchers

Graphic depicting how new CDT nanoagent works.
Illustration Credit: Parinaz Ghanbari.

Scientific Frontline: "At a Glance" Summary

• Main Discovery: A novel iron-based metal-organic framework (MOF) nanoagent has been developed to trigger dual chemical reactions within cancer cells, generating oxidative stress via hydroxyl radicals and singlet oxygen to eradicate malignant cells while sparing healthy tissue.
• Methodology: The researchers designed a chemodynamic therapy (CDT) agent that leverages the acidic and high-hydrogen peroxide microenvironment of tumors to catalyze the simultaneous production of hydroxyl radicals and singlet oxygen.
• Key Data: In preclinical studies involving mice with human breast cancer, systemic administration of the nanoagent resulted in complete tumor eradication and long-term prevention of recurrence with no observed systemic toxicity or adverse effects on healthy cells.
• Significance: This advancement overcomes limitations of existing CDT agents that typically generate only one type of reactive oxygen species or lack sufficient catalytic activity, offering a more potent and durable therapeutic benefit for cancer treatment.
• Future Application: The team plans to evaluate the therapeutic efficacy of this nanoagent in various other cancer types, including aggressive pancreatic cancer, to establish its broad applicability prior to human clinical trials.
• Branch of Science: Nanomedicine, Oncology, and Pharmaceutical Sciences

Purdue team announces new therapeutic target for breast cancer

Graduate student Addison Young (left) and Kyle Cottrell, assistant professor, both in Purdue’s department of biochemistry. Young and Cottrell have reported discovering a new therapeutic target for triple-negative breast cancer in the journal RNA.
Photo Credit: Courtesy of Purdue University

Scientific Frontline: "At a Glance" Summary

• Main Discovery: A specific double-stranded RNA (dsRNA)-binding protein called PACT has been identified as a novel therapeutic target for triple-negative breast cancer (TNBC), a deadly form of the disease that currently lacks targeted therapies.
• Methodology: Researchers utilized the gene-editing tool CRISPR-Cas9 to deplete PACT in various cell lines, allowing them to observe which cellular pathways became activated and to confirm PACT's role as a suppressor of the RNA-activated protein kinase (PKR).
• Key Data: The study established that PACT functions as a dimer—requiring the fusion of two monomers to operate—and that TNBC cells are particularly sensitive to its depletion, which triggers a "viral mimicry" state that can lead to cancer cell death.
• Significance: This research resolves a scientific controversy by confirming PACT acts as a suppressor rather than an activator of PKR; blocking PACT allows PKR to sense dsRNA and initiate stress responses that kill cancer cells, offering a strategy to treat TNBC without broad chemotherapy.
• Future Application: Scientists aim to develop molecules that specifically inhibit PACT dimerization, creating precise drugs for TNBC and potentially other cancer types that depend on this protein for survival.
• Branch of Science: Biochemistry and Oncology.
• Additional Detail: Unlike many therapeutic targets which are enzymes, PACT is a structural protein; therefore, treatment strategies must focus on physically preventing the binding of its two monomers rather than blocking enzymatic activity.

Optimized Solvent Design Improves Lymphatic Drug Delivery to Metastatic Lymph Nodes

Overview of Lymphatic Drug Delivery Systems (LDDS) and the Optimal Ranges of Solvent Osmolarity and Viscosity Depending on Therapeutic Strategies.
Illustration Credit: ©Taiki Shimano et al.

Scientific Frontline: "At a Glance" Summary

• Main Discovery: The optimization of solvent osmolarity and viscosity in Lymphatic Drug Delivery Systems (LDDS) significantly regulates drug pharmacokinetics and perinodal dynamics to improve treatment of metastatic lymph nodes.
• Methodology: Researchers injected therapeutic formulations directly into the sentinel lymph nodes of MXH10/Mo/lpr mice—a model featuring human-sized nodes—to monitor real-time changes in lymphatic and vascular flow based on varied solvent properties.
• Key Data: Increased solvent osmolarity was observed to promote blood inflow and expand lymphatic sinuses (drug pathways), while solvent viscosity acted as the dominant factor determining the duration of drug retention and the extent of delivery.
• Significance: The study provides critical guidelines for "tailor-made solvent design," directly validating the protocols for ongoing Phase I clinical trials at Iwate Medical University and Tohoku University Hospital.
• Future Application: Development of next-generation cancer therapies where drug solvent properties are customized to specific clinical goals, such as maximizing retention time or enhancing downstream distribution.
• Branch of Science: Biomedical Engineering, Oncology, and Pharmacology.
• Additional Detail: This research represents the first comprehensive demonstration of how fundamental physicochemical properties of solvents independently influence drug behavior during intranodal administration.

Lithium study yields insights in the fight against HIV

Ana Luiza Abdalla and Andrew Mouland in front of a flow cytometer at the Lady Davis Institute for Medical Research. The instrument was used to collect key data for the study
Photo Credit: Lucca Jones

Scientific Frontline: "At a Glance" Summary

• Main Discovery: Lithium treatment effectively prevents the reactivation of HIV in latent infected cells, keeping the virus dormant through a biological mechanism previously unidentified in this context.
• Methodology: Researchers utilized a novel fluorescence-based assay to distinguish between dormant and active virus in lab-grown human cells, testing lithium's efficacy while simultaneously disrupting the autophagy pathway to isolate the mechanism of action.
• Key Data: Experiments demonstrated that lithium's ability to suppress viral reactivation persisted even when the cell's autophagy (recycling) system was disabled, directly contradicting the prevailing hypothesis that autophagy was required for this effect.
• Significance: This finding supports the feasibility of a "functional cure"—strategies that keep the virus permanently dormant rather than eradicating it—and identifies a new biological target for maintaining HIV latency.
• Future Application: Development of new pharmaceutical agents that mimic lithium's viral suppression properties without causing the psychoactive side effects or toxicity associated with the drug's current clinical use.
• Branch of Science: Virology and Pharmacology
• Additional Detail: While lithium is an inexpensive and readily available drug, the authors explicitly warn against its current use by HIV patients due to significant side effects and the lack of human clinical trials for this specific indication.

Study Sheds Light on the Function of a Key Antibiotic-Producing Enzyme

Researchers have successfully replaced a section of the antibiotic-synthesizing enzyme PikAIII-M5, advancing our understanding of its structure and function and moving us closer to the creation of synthetic antibiotics.
Illustration Credit: ©Tohoku University

Scientific Frontline: "At a Glance" Summary

• Main Discovery: Researchers successfully engineered a chimeric version of the enzyme PikAIII-M5, a key component in pikromycin biosynthesis, by swapping its beta-ketoreductase domain to control the stereochemistry of macrolide chains.
• Methodology: The team utilized a synthetic substrate evaluation system to physically replace the beta-ketoreductase domain within the PikAIII-M5 enzyme with an alternative domain, subsequently analyzing how these structural modifications altered the enzyme's biochemical output.
• Key Data: The study validated that the beta-ketoreductase domain acts as an interchangeable module; its successful replacement demonstrated that specific domain swapping can predictably dictate the structural composition of the resulting macrolactone ring.
• Significance: This research establishes a verified "design guideline" for combinatorial biosynthesis, enabling more accurate predictions of chemical structures from genomic data and facilitating the engineering of complex, non-natural drug molecules.
• Future Application: The findings will be applied to create novel macrolide antibiotics with structures not found in nature, directly addressing the global crisis of antibiotic resistance and the shrinking pipeline of effective antimicrobial drugs.
• Branch of Science: Synthetic Biology, Biochemistry, and Pharmaceutical Sciences.
• Additional Detail: The researchers describe the strategic engineering process as analogous to "swapping interchangeable parts in a machine," emphasizing the high potential for modular manipulation in antibiotic development.

Purdue mRNA therapy delivery system proves to be shelf-stable, storable

The Proceedings of the National Academy of Sciences has published research about a Purdue University virus-mimicking platform technology that targets bladder cancer cells with mRNA therapies. The LENN platform scientists include, from left, Christina Ferreira, Saloni Darji, Bennett Elzey, Joydeep Rakshit, Feng Qu and David Thompson.
Photo Credit: Purdue University /Ali Harmeson

Scientific Frontline: "At a Glance" Summary

• Main Discovery: The LENN (Layer-by-layer Elastin-like Polypeptide Nucleic Acid Nanoparticle) platform successfully delivers mRNA therapies to bladder cancer cells while retaining full biological activity after being freeze-dried into a shelf-stable powder.
• Methodology: Researchers engineered a virus-mimicking dual-layer nanoparticle to condense and protect nucleic acids, then subjected the formulation to lyophilization (freeze-drying) and storage at -20°C to validate its stability and rehydration properties.
• Key Data: The lyophilized samples maintained complete structural integrity and functionality after three days of storage, successfully targeting upregulated receptors on tumor cells without triggering an immune response.
• Significance: This technology overcomes the severe cold-chain limitations of current lipid nanoparticle systems—which often require storage below -45°C—by providing a biomanufacturable, storable powder form that facilitates easier global distribution.
• Future Application: The team is upscaling the system for preclinical evaluation and initiating efficacy and safety studies in mouse models of bladder cancer.
• Branch of Science: Nanomedicine, Pharmaceutical Chemistry, and Oncology.
• Additional Detail: Multiple reaction monitoring (MRM) profiling confirmed that the system utilizes natural entry pathways and avoids immune detection, potentially solving the "redosing" clearance issues associated with traditional viral vectors.

What Is: Psychedelic Renaissance

The current "Psychedelic Renaissance" is not a new discovery but a recovery of lost knowledge.
Image Credit: Scientific Frontline

The Fourth Wave of Psychiatry

The field of psychiatry is currently undergoing its most significant paradigm shift since the introduction of the first psychopharmaceuticals in the mid-20th century. For decades, the standard of care for mental health disorders has been dominated by the monoamine hypothesis—the idea that regulating neurotransmitters like serotonin, dopamine, and norepinephrine through daily maintenance medication can rectify chemical imbalances. However, a growing body of evidence, accumulated largely over the last two decades and culminating in the pivotal events of 2024 and 2025, suggests that this model is incomplete. We are witnessing the rise of a "fourth wave" of psychiatry, characterized by the use of psychedelics: compounds that do not merely suppress symptoms but appear to catalyze profound, rapid, and durable healing through mechanisms of neuroplasticity and network reorganization.

This report serves as an exhaustive analysis of the current state of psychedelic medicine as of late 2025. It moves beyond the simplistic "shroom boom" narratives to dissect the complex neurobiology, the rigorous clinical trials, and the volatile regulatory landscape that defines this sector. The subject matter encompasses "classic" psychedelics like psilocybin and lysergic acid diethylamide (LSD), which primarily target the serotonin 2A receptor, as well as "atypical" psychedelics or entactogens like 3,4-methylenedioxymethamphetamine (MDMA).

Researchers find breast cancer drug boosts leukemia treatment

Jeffrey Tyner, Ph.D., and Melissa Stewart, Ph.D., led a team at OHSU that discovered a new drug combination that may help people with acute myeloid leukemia.
Photo Credit: OHSU/Christine Torres Hicks

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common frontline therapies.

In a study published in Cell Reports Medicine, researchers analyzed more than 300 acute myeloid leukemia, or AML, patient samples and found that pairing venetoclax, a standard AML drug, with palbociclib, a cell-cycle inhibitor currently approved for breast cancer, produced significantly stronger and more durable anti-leukemia activity than venetoclax alone. The findings were confirmed in human tissue samples as well as in mouse models carrying human leukemia cells.

“Of the 25 drug combinations tested, venetoclax plus palbociclib was the most effective. That really motivated us to dig deeper into why it works so well, and why it appears to overcome resistance seen with current therapy,” said Melissa Stewart, Ph.D., research assistant professor in the OHSU School of Medicine and Knight Cancer Institute and lead author of the study.

More than 20,000 Americans are diagnosed with AML each year, making it one of the most common types of leukemia — and one of the most aggressive.